SPC-15
Stress-Induced Affective Disorders (e.g., PTSD)
Pre-INDPre-IND submitted
Key Facts
Indication
Stress-Induced Affective Disorders (e.g., PTSD)
Phase
Pre-IND
Status
Pre-IND submitted
Company
About Silo Pharma
Silo Pharma is a Nasdaq-listed biotech focused on developing novel therapeutics for central nervous system disorders and chronic pain through a capital-efficient licensing and development model. Its core strategy involves in-licensing promising candidates from academic partners and advancing them via the FDA's 505(b)(2) regulatory pathway to reduce time and cost. Key assets include SPC-15, a prophylactic intranasal treatment for stress-induced disorders, and SP-26, a ketamine-based implant for fibromyalgia. The company aims to address significant unmet medical needs in large, growing markets with limited treatment options.
View full company profile